Cytokinetics Reports Second Quarter 2024 Financial Results
08 août 2024 16h00 HE
|
Cytokinetics, Incorporated
Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten;Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
01 août 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Call for Proposals for Corporate Giving Program
30 juil. 2024 07h30 HE
|
Cytokinetics, Incorporated
Program Augments Existing Patient Advocacy and Professional Society Donationsto Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September 16th, 2024 SOUTH...
Cytokinetics to Announce Second Quarter Results on August 8, 2024
25 juil. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at...
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
16 juil. 2024 07h30 HE
|
Cytokinetics, Incorporated
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
03 juil. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
17 juin 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 juin 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics to Participate in June Investor Conferences
29 mai 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Announces Closing of Public Offering of Common Stock
28 mai 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of...